Elderwood at Burlington: Psychotropic Drug Misuse - VT
Federal inspectors found the facility violated rules designed to prevent unnecessary psychotropic medications during an August complaint investigation. The violation centered on a single resident with vascular dementia who received Lorazepam without proper safeguards.
Resident #2 suffers from vascular dementia, a condition that damages reasoning, planning, judgment and memory through impaired blood flow to the brain. The resident also has Stage 2 chronic kidney disease and chronic obstructive pulmonary disease. A July mental status assessment scored the resident a 9, indicating cognitive impairment.
On July 23, a physician ordered Lorazepam 0.5 milligrams to be given by mouth every six hours as needed for itching and anxiety. Federal regulations require such orders to include a stop date within 14 days to prevent medications from becoming chemical restraints that unnecessarily sedate residents.
This order had no stop date.
Staff administered the Lorazepam to Resident #2 eight separate times between July 23 and August 11, when inspectors arrived. Each dose represented a potential violation of the resident's right to be free from chemical restraints.
The Director of Nursing confirmed during an August 11 interview that the Lorazepam order lacked the required 14-day stop date. The admission came at 11:45 AM as inspectors documented their findings.
Chemical restraints represent a significant concern in nursing homes, particularly for residents with dementia. Unlike physical restraints that limit movement, chemical restraints use medications to control behavior or limit a resident's ability to function normally. Federal regulations recognize that psychotropic medications can effectively restrain residents when used improperly.
The 14-day limit exists specifically to force medical teams to regularly reassess whether residents truly need these powerful medications. Without automatic expiration dates, orders can continue indefinitely, potentially sedating residents far longer than medically necessary.
Lorazepam belongs to a class of drugs called benzodiazepines, commonly prescribed for anxiety but carrying significant risks for elderly patients. The medication can cause confusion, falls, and increased cognitive impairment, particularly dangerous for someone already struggling with dementia.
Vascular dementia affects the resident's ability to make informed decisions about their care. The condition results from reduced blood flow to brain tissue, gradually destroying the cognitive functions needed for daily life. Patients with this diagnosis require extra protection from medications that could further compromise their mental capacity.
The facility's violation occurred despite clear regulatory guidance. Federal rules specifically prohibit using psychotropic medications as chemical restraints and require facilities to demonstrate that residents actually need these drugs rather than using them for staff convenience.
Elderwood at Burlington's failure represents exactly what federal regulations aim to prevent. A cognitively impaired resident received a sedating medication repeatedly without the safety mechanism designed to trigger medical review.
The inspection classified this as causing minimal harm or potential for actual harm, affecting few residents. However, for Resident #2, the impact was direct and personal. Eight doses of an anxiety medication administered without proper oversight to someone already struggling with impaired reasoning and memory.
Inspectors found the violation during a complaint investigation, suggesting someone raised concerns about care at the facility. The timing indicates the improper medication administration was occurring when the complaint was filed.
The Director of Nursing's confirmation that the order lacked required safety measures demonstrates institutional awareness of the problem. Yet the medication continued to be administered to a vulnerable resident who may not have been able to advocate for proper care.
Federal regulations exist to protect residents like #2 from becoming chemically restrained through improper medication use. This case illustrates how a missing stop date can transform legitimate medical treatment into a regulatory violation that potentially compromises a resident's quality of life and cognitive function.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Elderwood At Burlington from 2025-08-11 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: June 20, 2026 · Our methodology
Elderwood at Burlington in Burlington, VT was cited for violations during a health inspection on August 11, 2025.
Federal inspectors found the facility violated rules designed to prevent unnecessary psychotropic medications during an August complaint investigation.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.